IN2014CN02805A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02805A IN2014CN02805A IN2805CHN2014A IN2014CN02805A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A IN 2805CHN2014 A IN2805CHN2014 A IN 2805CHN2014A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A
- Authority
- IN
- India
- Prior art keywords
- compounds
- medicaments
- variables
- inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547301P | 2011-10-14 | 2011-10-14 | |
| PCT/US2012/059932 WO2013056034A1 (fr) | 2011-10-14 | 2012-10-12 | Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02805A true IN2014CN02805A (fr) | 2015-07-03 |
Family
ID=47116434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2805CHN2014 IN2014CN02805A (fr) | 2011-10-14 | 2010-08-18 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9079929B2 (fr) |
| EP (1) | EP2766347B1 (fr) |
| JP (1) | JP6033318B2 (fr) |
| CN (1) | CN103987696B (fr) |
| ES (1) | ES2579832T3 (fr) |
| IN (1) | IN2014CN02805A (fr) |
| WO (1) | WO2013056034A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5844287B2 (ja) | 2010-02-11 | 2016-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としてのマクロ環 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| LT2766346T (lt) | 2011-10-14 | 2017-06-12 | Bristol-Myers Squibb Company | Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai |
| IN2014CN02806A (fr) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| IN2014CN02805A (fr) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| US9758480B2 (en) | 2012-07-19 | 2017-09-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1-(cycloalkyl-carbonyl)proline derivative |
| KR20150038372A (ko) | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| CA2880898A1 (fr) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Recepteurs p1 de la dihydropyridone en tant qu'inhibiteurs du facteur xia |
| HRP20180465T1 (hr) | 2012-10-12 | 2018-05-04 | Bristol-Myers Squibb Company | Kristalni oblici inhibitora faktora xia |
| EP2906552B1 (fr) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Composés de tetrahydroisoquinoline substitués par guanidine en tant qu'inhibiteurs de factor xia |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| CN105307493A (zh) * | 2013-03-05 | 2016-02-03 | 拜耳作物科学股份公司 | 酰基磺酰胺用于提高植物产量的用途 |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| EP3054944B1 (fr) | 2013-10-07 | 2019-12-04 | Merck Sharp & Dohme Corp. | Inhibitors du facteur xia |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
| EP3104703B1 (fr) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| EP3104702B1 (fr) | 2014-02-11 | 2022-08-10 | Merck Sharp & Dohme LLC | Inhibiteurs du facteur xia |
| WO2015164308A1 (fr) | 2014-04-22 | 2015-10-29 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| US9365520B2 (en) | 2014-07-01 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9868727B2 (en) | 2014-07-28 | 2018-01-16 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｆｘｉａ阻害剤であるジアミドマクロ環 |
| WO2016046166A1 (fr) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| ES2716417T3 (es) * | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| US10160750B2 (en) | 2015-06-19 | 2018-12-25 | Bristol-Myers Squibb Company | Diamide macrocycles as factor XIa inhibitors |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| ES2871111T3 (es) | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático |
| CN107849026B (zh) | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
| US10336730B2 (en) | 2015-08-05 | 2019-07-02 | Bristol-Myers Squibb Company | Substituted glycine derived FXIA inhibitors |
| WO2017074833A1 (fr) | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Dérivé spirocarbamate macrocyclique comme inhibiteurs du facteur xia, compositions pharmaceutiquement acceptables et leur utilisation |
| BR112018008506B8 (pt) | 2015-10-29 | 2023-12-05 | Merck Sharp & Dohme | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos |
| WO2017123518A1 (fr) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Immunomodulateurs d'aminotriazole pour traiter des maladies auto-immunes |
| EP3431472B1 (fr) * | 2016-03-17 | 2023-05-03 | Checkmate Therapeutics Inc. | Nouveau composé pour inhiber la nicotinamide phosphoribosyltransférase et composition contenant le nouveau composé |
| US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN109721539B (zh) * | 2017-10-27 | 2021-07-09 | 天津药物研究院有限公司 | 吡唑酰胺类衍生物及其制备方法和用途 |
| CN109867660A (zh) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的四氢异喹啉酰胺化合物及其药物用途 |
| EP3778597B1 (fr) * | 2018-03-28 | 2025-05-28 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dérivé de tétrahydro-isoquinoline, son procédé de préparation et ses applications |
| EP3976027B1 (fr) * | 2019-05-30 | 2025-11-05 | Merck Sharp & Dohme LLC | Dérivés de quinoléine en tant qu'inhibiteurs d'activation du facteur xi |
| EP4125892A4 (fr) * | 2020-04-01 | 2024-04-03 | Merck Sharp & Dohme LLC | Inhibiteurs d'activation du facteur xi |
| EP4149917B1 (fr) * | 2020-05-12 | 2025-07-30 | Merck Sharp & Dohme LLC | Inhibiteurs d'activation du facteur xi |
| EP3978487A1 (fr) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | Dérivés de 2-(3-pyridine-2-yl-4-quinoline-4-yl-pyrazol-1-yl)-acétamide comme inhibiteurs du récepteur du facteur de croissance transformant bêta i/alk5 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
| EP0028489B1 (fr) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Dérivés d'enzymes et leur préparation |
| DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| WO1996034010A2 (fr) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibiteurs de la farnesyle transferase |
| US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU717298B2 (en) | 1996-04-03 | 2000-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| PL204619B1 (pl) | 1998-03-19 | 2010-01-29 | Vertex Pharma | Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| EP1016663A1 (fr) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Dérivés de l'acide malonique, procédé pour leur préparation, leur utilisation comme médicaments et compositions les contenant (inhibiteurs du facteur Xa ) |
| CA2358578A1 (fr) | 1999-01-02 | 2000-07-13 | Aventis Pharma Deutschland Gmbh | Nouveaux derives d'acide malonique, procedes de preparation de ces derives, leur utilisation et compositions pharmaceutiques les contenant (inhibition de l'activite du facteur xa) |
| CA2369378A1 (fr) | 1999-04-09 | 2000-10-19 | Basf Aktiengesellschaft | Inhibiteurs de faible poids moleculaire des proteases du complement |
| CA2383008A1 (fr) | 1999-06-14 | 2000-12-21 | Amanda Jane Lyons | Composes |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EP1125925A1 (fr) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Dérivés amines pour le traitement de l'apoptose |
| JP2004507456A (ja) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AU2002341693B2 (en) | 2001-09-21 | 2008-05-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
| US6649606B1 (en) * | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7544699B2 (en) * | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| BRPI0513310A (pt) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| CN101137412B (zh) | 2005-01-13 | 2012-11-07 | 布里斯托尔-迈尔斯·斯奎布公司 | 用作凝血因子XIa抑制剂的取代的二芳基化合物 |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| CA2612279C (fr) | 2005-06-17 | 2014-04-15 | Basf Aktiengesellschaft | Procede de production de renforcateurs de blanchiment |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5225098B2 (ja) | 2005-12-14 | 2013-07-03 | ブリストル−マイヤーズ スクイブ カンパニー | 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| NZ575652A (en) | 2006-08-23 | 2011-08-26 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| ES2546815T3 (es) | 2006-12-15 | 2015-09-28 | Bristol-Myers Squibb Company | Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa |
| KR20100037600A (ko) | 2007-06-13 | 2010-04-09 | 브리스톨-마이어스 스큅 컴퍼니 | 응고 인자 억제제로서의 디펩티드 유사체 |
| CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| WO2010151317A1 (fr) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Acides hydroxamiques substitués et leurs utilisations |
| WO2011002520A2 (fr) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Inhibiteurs à petite molécule de l'activité de parp |
| EP2462123B1 (fr) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | Dérivés de pyrimidine trisubstitués en positions 4,5,6 en tant qu' inhibiteurs du facteur ixa |
| JP5844287B2 (ja) | 2010-02-11 | 2016-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としてのマクロ環 |
| EP2729150B1 (fr) | 2011-07-08 | 2016-09-14 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur ixa |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| LT2766346T (lt) | 2011-10-14 | 2017-06-12 | Bristol-Myers Squibb Company | Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai |
| IN2014CN02806A (fr) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| IN2014CN02805A (fr) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| WO2013093484A1 (fr) | 2011-12-21 | 2013-06-27 | Ono Pharmaceutical Co., Ltd. | Dérivés de pyridinone et de pyrimidinone comme inhibiteurs du facteur xia |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| US20140350034A1 (en) | 2012-01-27 | 2014-11-27 | Novartis Ag | Aminopyridine derivatives as plasma kallikrein inhibitors |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| US9783614B2 (en) | 2012-05-10 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof |
| US9758480B2 (en) | 2012-07-19 | 2017-09-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1-(cycloalkyl-carbonyl)proline derivative |
| CA2880898A1 (fr) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Recepteurs p1 de la dihydropyridone en tant qu'inhibiteurs du facteur xia |
| KR20150038372A (ko) | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
-
2010
- 2010-08-18 IN IN2805CHN2014 patent/IN2014CN02805A/en unknown
-
2012
- 2012-10-12 JP JP2014535916A patent/JP6033318B2/ja not_active Expired - Fee Related
- 2012-10-12 US US14/350,411 patent/US9079929B2/en active Active
- 2012-10-12 EP EP12780357.5A patent/EP2766347B1/fr not_active Not-in-force
- 2012-10-12 ES ES12780357.5T patent/ES2579832T3/es active Active
- 2012-10-12 WO PCT/US2012/059932 patent/WO2013056034A1/fr not_active Ceased
- 2012-10-12 CN CN201280061628.1A patent/CN103987696B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20140274960A1 (en) | 2014-09-18 |
| CN103987696B (zh) | 2016-12-21 |
| EP2766347A1 (fr) | 2014-08-20 |
| EP2766347B1 (fr) | 2016-05-04 |
| CN103987696A (zh) | 2014-08-13 |
| JP2014530240A (ja) | 2014-11-17 |
| ES2579832T3 (es) | 2016-08-17 |
| JP6033318B2 (ja) | 2016-11-30 |
| US9079929B2 (en) | 2015-07-14 |
| WO2013056034A1 (fr) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02806A (fr) | ||
| TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
| MX361759B (es) | Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico. | |
| MX2015000919A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| PH12014500199A1 (en) | Indazoles | |
| MY201397A (en) | Primidinones as factor xia inhibitors | |
| IN2015DN00598A (fr) | ||
| IN2014MN02658A (fr) | ||
| NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
| IN2015DN01156A (fr) | ||
| MY162936A (en) | Macrocycles as factor xia inhibitors | |
| MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| IN2014MN02657A (fr) | ||
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| IN2015DN00185A (fr) | ||
| IN2014CN03803A (fr) | ||
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| GB201209587D0 (en) | Therapeutic compounds | |
| IN2014DN06869A (fr) | ||
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. |